| 1 |
潘静, 朱斌, 王素丽, 等. 伊马替尼治疗慢性髓系白血病(慢性期)少见类型皮疹1例 [J/OL]. 中华临床医师杂志(电子版), 2023, 17(1): 102-104.
|
| 2 |
Sgherza N, Abruzzese E, Perla G, et al. Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature [J]. Ther Clin Risk Manag, 2017, 13: 751-755.
|
| 3 |
Duncavage EJ, Bagg A, Hasserjian RP, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia [J]. Blood, 2022, 140(21): 2228-2247.
|
| 4 |
Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome [J]. Blood, 2008, 111(12): 5505-5508.
|
| 5 |
Brioli A, Lomaia E, Fabisch C, et al. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era-analysis of the European Leukemia Net Blast Phase Registry [J]. Leukemia, 2024, 38(5): 1072-1080.
|
| 6 |
Tsuboi K, Komatsu H, Miwa H, et al. Lymphoid blastic crisis of chronic myelogenous leukaemia with inv(16)(p13;q22) [J]. Leuk Res, 2002, 26(8): 771-774.
|
| 7 |
Merzianu M, Medeiros LJ, Cortes J, et al. Inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases [J]. Am J Clin Pathol, 2005, 124(5): 807-814.
|
| 8 |
Roth CG, Contis L, Gupta S, et al. De novo acute myeloid leukemia with Philadelphia chromosome (BCR-ABL) and inversion 16 (CBFB-MYH11): report of two cases and review of the literature [J]. Leuk Lymphoma, 2011, 52(3): 531-535.
|
| 9 |
Wang YY, Ding WJ, Jiang F, et al. Coexistence of p210BCR-ABL and CBFβ-MYH11 fusion genes in myeloid leukemia: A report of 4 cases [J]. Oncol Lett, 2017, 14(5): 5171-5178.
|
| 10 |
Opatz S, Bamopoulos SA, Metzeler KH, et al. The clinical mutatome of core binding factor leukemia [J]. Leukemia, 2020, 34(6): 1553-1562.
|
| 11 |
Schaefer EJ, Wang HC, Karp HQ, et al. BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes [J]. Blood Cancer Discov, 2022, 3(2): 116-135.
|
| 12 |
Huang BJ, Smith JL, Wang YC, et al. CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes [J]. Blood Adv, 2021, 5(23): 4963-4968.
|
| 13 |
Chan WW, Wise SC, Kaufman MD, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036[J]. Cancer Cell, 2011, 19(4): 556-568.
|
| 14 |
DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia [J]. Blood, 2019, 133(1): 7-17.
|
| 15 |
Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia [J]. Cancer Discov, 2020, 10(4): 536-551.
|
| 16 |
Wang JD, Wang JX, Lin ZL, et al. GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells [J]. Cell Death Discov, 2025, 11(1): 229.
|